Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Pathology

‘First of its kind’ update for cancer surveillance standards

September 2024—New cancer surveillance standards for tumor site, histology, and behavior code combinations and associated terms rolled out this year, after pathologists reviewed the combinations in an all-new effort. It’s an initiative known as Cancer PathCHART, short for Cancer Pathology Coding Histology and Registration Terminology, led by the National Cancer Institute with the support of 10 collaborating organizations, among them the CAP and the World Health Organization. “Nobody but the NCI could’ve done this. It’s been a great project,” says Kay Washington, MD, PhD, professor of pathology at Vanderbilt University Medical Center and a past member of the CAP Cancer Committee and American Joint Committee on Cancer.

AP lab panel on LDTs, digital path, workforce

August 2024—Digital pathology, FDA oversight of laboratory-developed tests, and the workforce shortage took center stage when CAP TODAY publisher Bob McGonnagle convened a roundtable online to talk about anatomic pathology laboratories. The shortage of pathologists, in particular, “is even greater than one might realize because of generational expectations around work-life balance,” said Andrew Bellizzi, MD, who applauds such balance but notes its significance. Their June 18 conversation follows.

Cytopathology in focus—Low-grade pancreatic neuroendocrine tumors in small samples: Grading challenges

August 2024—Two to five percent of pancreatic tumors are pancreatic neuroendocrine neoplasms, of which more than 90 percent are well-differentiated pancreatic neuroendocrine tumors (PanNETs). The current World Health Organization classification stratifies PanNETs into three histological grades based on mitotic count and Ki-67 proliferation index. Low-grade PanNETs (grades one and two) are morphologically indistinguishable and have characteristic neuroendocrine cytomorphologic features: a dispersed/loosely cohesive smear pattern composed of small-to-medium monomorphic cells with occasional plasmacytoid appearance; amphophilic, granular, or vacuolated cytoplasm; round nuclei; and coarse salt-and-pepper chromatin.

Digging into the interpretation of TSH results

Charna Albert May 2024—In a time of wellness testing and high rates of levothyroxine prescribing for hypothyroidism, it may also be time to rethink TSH test result interpretation. Laboratory testing is more accessible now than it used to be and patients are more involved in their own care. “You’re trying to give the patient access and ability to take care of their own health. But the double-edged sword is you can start over-ordering things, and the way we’ve designed lab

Labs juggle string of LDT unknowns

July 2024—Like a long-awaited second act, the FDA’s final rule regulating laboratory-developed tests as medical devices took the stage this spring. As with any FDA performance, this one opened to mixed reviews.

The spring curtain-raising followed the earlier proposed rule from last October, which drew some 6,500 responses during the public comment period. If that was an out-of-town tryout, no one quite knew what to expect from the rewrite, or if there would even be one.

As it turns out, there were indeed changes, but they didn’t necessarily bring clarity. As Jane Pine Wood, counsel for McDonald Hopkins, puts it, the final rule “certainly raised a whole lot more questions than it answered.”

The rule calls for a four-year, five-stage phaseout policy with the FDA enacting greater oversight of in vitro diagnostic products that are offered as LDTs.

Stage one, beginning on May 6, 2025, calls for labs to comply with medical device reporting requirements, correction and removal reporting requirements, and quality system requirements regarding complaint files.

Mayo pathologists create and test their own AI algorithms

July 2024—A Mayo Clinic project is “democratizing artificial intelligence,” its leaders say, by enabling pathologists with varying levels of AI expertise—most of whom had never before participated in an AI project—to create and implement algorithms.

Recommendations issued on PD-L1, TMB testing

July 2024—In patients with advanced non-small cell lung cancer, a validated PD-L1 immunohistochemistry expression assay should be used, with other targetable genomic biomarker assays where appropriate, for the selection of immune checkpoint inhibitor therapies. And the appropriate validation should be performed on all specimen types and fixatives. Those are two of the six recommendations of the CAP, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation, released in April and now in print in their PD-L1 and tumor mutation burden testing guideline for the selection of such therapies.

How rapid autopsies bridge clinical care and research

June 2024—Meagan Chambers, MD, MS, MSc, feels like she has signed on for a life of being on call for 2 AM autopsies, and she says nothing could please her more. She is a neuropathology fellow at the University of Washington and does many of the rapid autopsies that make possible a range of human research that would otherwise be limited or out of reach.

Idiopathic multicentric Castleman disease

June 2024—Idiopathic multicentric Castleman disease, which is driven by a cytokine storm with an unknown cause, is a difficult diagnosis and one that’s often delayed, owing to the disease’s rarity and nonspecific symptoms. “Patients often bounce around for months, or even years, to different specialties, based on how they present, before they are diagnosed,” said Jadee Neff, MD, PhD, assistant professor of pathology, Duke University Medical Center, in a CAP TODAY webinar in February made possible by a special educational grant from Recordati Rare Diseases.

MARKETPLACE

TRENDING